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Tumors cells can release natural killer (NK) cell ligands for activating receptor NKG2D that are thought to
inhibit NK cell function. In a recent issue of Science, Deng et al. (2015) show that, unexpectedly, a soluble
NKG2D ligand can enhance anti-tumor NK cell activity.Natural killer (NK) cells of the innate
immune system were first named and
described as a cell population with a nat-
ural ability to kill tumor cells in vitro.
Indeed, simply mixing NK cells with tumor
cells results in NK cell activation and
tumor cell killing without the addition of
exogenous factors. As more was learned
about the mechanism of NK cell regula-
tion, it became clear that NK cell activa-
tion is regulated by a balance of positive
and negative signals, largely delivered
through constitutively expressed mem-
brane receptors interacting with self-li-
gands. Thus, it is the balance of expres-
sion of the ligands for these receptors
that ultimately determines whether an
NK cell becomes activated to kill the
target cell (Yokoyama, 2005). The first
(Ly49) and best-characterized NK recep-
tors, including the killer inhibitory receptor
(KIR) group, recognize subsets of MHC
class I molecules independently of the
bound peptide (Karlhofer et al., 1992).
Killer activating receptors (KAR) are also
diverse—a common thread among the
even more diverse KAR ligands is that
they are upregulated by various forms of
cellular stress ranging from highly acti-
vated Ras-pathway signaling and DNA
damage responses, both of which are
common in many cancers (Raulet and
Guerra, 2009; Gasser et al., 2005). The
best characterized KAR is natural-killer
group 2, member D (NKG2D), which has
many ligands that are MHC class I-related
but do not present peptides like conven-
tional MHC class I. NKG2D is associated
with one of two adaptors that contain im-
mune tyrosine activating motifs that
become phosphorylated upon NKG2D
crosslinking and in turn bind kinases that
mediate NK cell activation (Lanier, 2009).These features of NK cell signaling and
activation explain much about the physio-
logic role of NK cells in the response to
viral infection. Most viral infections stress
infected cells, inducing upregulation of li-
gands for KAR, thus shifting the balance
toward NK cell activation. In addition,
many viruses express proteins that down-
regulate MHC class I expression as a
means of evading recognition by classic
CD8 cytotoxic T lymphocytes (CTLs);
this mechanism of immune evasion is
countered by enhanced NK activation
due to decreased engagement of MHC
class I-specific NK cell inhibitory recep-
tors. Children with homozygous muta-
tions in various genes that impair NK cell
function are susceptible to certain viral in-
fections (Eidenschenk et al., 2006).
Cancer cells generally exist in a con-
stant state of cellular stress due to hypox-
ia, chronic proliferative signals (i.e., due to
constitutively activating Ras mutations),
and ongoing genomic instability. Not sur-
prisingly, many therefore upregulate KAR
ligands on their surface, making them
susceptible to NK cell killing. Similar to
viruses, some cancers down-modulate
MHC class I, making them further suscep-
tible to NK cell killing. As with CD8 CTL
recognition, cancers must develop mech-
anisms to evade NK cell killing in order to
survive. Understanding these mecha-
nisms is critical because it will provide
novel targets for cancer immunotherapy
that complement the expanding arma-
mentarium of immunotherapies aimed at
conventional anti-tumor T cells.
One mechanism proposed for how
evasion of NKG2D-dependent tumor
killing by NK cells is secretion of soluble
NKG2D ligands that bind NKG2D in a
fashion that down-modulates NKG2D onImmunityNK cells without triggering it. Because
NKG2D is believed to require dimerization
by membrane-expressed ligands, solu-
ble monomeric ligand is not activating
(Figure 1, bottom). Experimental evidence
for this hypothesis was first provided by
Spies and colleagues, who focused on a
major human ligand for NKG2D, termed
MICA (as well as its homolog, MICB).
They demonstrated that certain human
tumors released soluble MICA and/or
MICB and that the soluble ligands indeed
down-modulated NKG2D on human
NK cells and inhibited their activation
in vitro. Some correlative evidence in hu-
mans (see below) supports this model,
and antibodies that bind and clear soluble
MICA/B have indeed been proposed for
immunotherapy (Groh et al., 2002).
In striking contrast to this model, Deng
et al. present a very different picture of tu-
mor-NK cell dynamics in the latest issue
of Science (Deng et al., 2015) (Figure 1,
bottom). Using elegant murine models,
they show that engineering tumors to
secrete a soluble form of a different
NKG2D ligand, MULT-1, actually results
in inhibition of tumor growth. They go on
to use a combination of in vitro binding
and functional experiments, as well as
in vivo gene deficiency experiments (us-
ing mice deficient in NKG2D [Klrk1] and
mice deficient in genes encoding two
major murine NKG2D ligands, Rae1d
and Rae1e) to support a model in which
chronic interaction of membrane-bound
RAE-1 with NKG2D actually leads to
down-modulation of NKG2D and also
functional ‘‘desensitization’’ or ‘‘anergy’’
of NK cells (analogous to the exhaustion
model of CD8 T cells chronically exposed
to cognate antigen). Soluble MULT1
competes with the membrane-bound42, April 21, 2015 ª2015 Elsevier Inc. 605
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Figure 1. Two Different Models for Tumor Resistance to NK Cell Killing
(Top) Spies and colleagues, based on human data, hypothesize that release of soluble MICA and MICB
down-modulates NKG2D on NK cells, thereby rendering them insensitive to triggering by membrane-
bound MICA and MICB on tumor cells.
(Bottom)Raulet andcolleagues, basedonmurinedata, hypothesize that chronic engagement ofNKG2Dby
Rae1 highly expressed on tumor-associated macrophages desensitizes (along with NKG2D down-modu-
lation) NKcells. SolubleMULT-1blocks this desensitization and leads to tumor killing by activatedNKcells.
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gates NKG2D down-modulation and NK
cell desensitization. Not only is this
desensitization effect diminished (i.e.,
NK cell activity is increased) in Rae1d/
Rae1e/ mice, but also in Klrk1/
mice. This finding suggests that chronic
RAE-1-NKG2D interactions inhibit NK
cell responses mediated by other (non-
NKG2D) KARs as well. In tumors, they
find that myeloid cells express high levels
of RAE-1 molecules on their surface and
are thus proposed to be the major source
of NK cell-desensitizing chronic NKG2D
engagement. In contrast to the Spies
model, the implication of the Deng-
Raulet model is that treatment of
cancer patients with soluble NKG2D li-
gands could enhance anti-tumor NK
responses.606 Immunity 42, April 21, 2015 ª2015 ElsevHow can we reconcile these two quite
opposing models? One resolution, which
emphasizes the complexity of this system
and its therapeutic modulation, stems
from the differences between murine
and human NKG2D ligands. Whereas
both mice and humans use the RAE-1
family members (the human versions
commonly termed ULBP), which seem to
represent orthologs between mouse and
human, MULT-1 has no human ortholog
and MICA and MICB have no known mu-
rine orthologs. Furthermore, the affinity of
MULT-1 for NKG2D is roughly 100-fold
higher than the affinity of MICA or MICB.
Thus, although the biology of NK regula-
tion at the 30,000-foot level is likely similar
inmouse and human, the effect of specific
ligands in mouse versus human might be
very different. Supportive evidence forier Inc.the Spies model in human cancer comes
from interesting findings of Dranoff and
colleagues (Jinushi et al., 2006) that
certain patients treated with cancer
vaccines or anti-CTLA-4 develop natural
anti-MICA antibodies associated with a
decrease in serum levels of soluble
MICA and an increase in NKG2D levels
on circulating NK cells relative to levels
prior to development of the antibody
response. This is associated with
increased NK cell function in vitro. These
findings, while correlative, have been
used to argue for the generation of
monoclonal antibodies to MICA that clear
soluble MICA while not blocking the
MICA-NKG2D interaction.
More experimentation will be necessary
to determine whether the findings of Deng
et al. in mice can be translated to human
cancers because, of course, human can-
cer is theultimatemodel for humancancer.
However, the study reveals that the role of
NKG2D ligands in cancer might be more
complicated than was previously appreci-
ated and opens up a new avenue of inves-
tigation for immunotherapy.REFERENCES
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